Recent Data Presentation Highlights Consistent Complete Response Rate and Strong Durability at Six-Months in Evaluable Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Completion of UGN-101 Rolling NDA Submission to the FDA On Track for 2H 2019 Pre-Commercial Activities and

Complete Response (CR) Rate Consistent at 59 Percent Six-month Durability Strong with 89 Percent of Evaluable Patients Remaining in CR Full Phase 3 Data Anticipated for 2H 2019 NEW YORK --(BUSINESS WIRE)--May 5, 2019-- UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company

Conference Call and Webcast Scheduled for 8:30 AM ET NEW YORK --(BUSINESS WIRE)--May 2, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019 , prior to the open of the market.

Focused Agreement is on Therapeutic Area of Mutual Interest NEW YORK --(BUSINESS WIRE)--Apr. 23, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered into an

NEW YORK --(BUSINESS WIRE)--Apr. 5, 2019-- UroGen Pharma Ltd.  (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced a new presentation from the pivotal Phase 3 OLYMPUS trial of UGN-101 (mitomycin gel) for

NEW YORK --(BUSINESS WIRE)--Mar. 5, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in March: Cowen and Company 39 th Annual Health Care Conference Tuesday, March 12 th 11:20AM Eastern Time Boston, MA Oppenheimer 29 th Annual

On Track to Complete UGN-101 Rolling NDA Submission to the FDA in 2H 2019 Acceleration of Pre-Commercial Activities and Infrastructure Buildout Underway to Support the Potential U.S. Approval and Launch of UGN-101 in 1H 2020 Initial Data from UGN-102 Trial Anticipated in 2019 Conference Call and

Conference Call and Webcast Scheduled for 8:30 AM ET NEW YORK --(BUSINESS WIRE)--Feb. 21, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report fourth quarter and full year 2018 financial results on Thursday, February 28, 2019 , prior to the open of the market.

NEW YORK --(BUSINESS WIRE)--Jan. 28, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the closing of its previously announced public offering of

NEW YORK --(BUSINESS WIRE)--Jan. 22, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary